Health & Fitness
Health and Fitness
Health and Fitness
Wed, June 30, 2010
Tue, June 29, 2010 Spencer Pharmaceutical Announces Its Agreement With One of Canada's Premier University Research Centers
BOSTON, MA--(Marketwire - June 29, 2010) - Spencer Pharmaceutical Inc. (
Spencer Pharmaceutical has a very unique business model due to its privileged relationships with world class researchers and their facilities. These relationships allow Spencer to acquire specific technologies and patents with a focus targeting certain diseases and accelerated "time to market." Spencer's role will be to develop the applications from the platforms technologies while marketing to industrial and commercial partners.
In light of the following, Dr. Max Arella, CEO of Spencer, is proud to announce an agreement with UQAM (University of Quebec in Montreal), whereby Spencer has already invested in the ongoing research and has made a financial commitment to fund the research until commercialization.
The research center is headed by Dr. Mircea Mateescu and his team notably Dr. Le Tien Canh. As part of the agreement, Spencer has acquired the rights to develop a submitted patented technology for many applications for the treatment of metabolic syndrome and other chronic diseases. "This patent is related to a new drug-delivery and gastric protection matrix, we believe that with the expertise of Dr. Mateescu and Dr. Le Tien Canh, his closest collaborator, will allow the rapid development of a new formulated drug that is a blockbuster for the treatment of diabetes," stated Dr. Max Arella. Furthermore, "Spencer's revenue model and business plan calls for the acquisition of technologies that don't require massive initial investments with the goal to generate revenues in the very near term unlike Spencer's peers in the Biotech Industry," added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information
About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
